المؤلفون: Elizaga ML; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Li SS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Kochar NK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Wilson GJ; Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America., Allen MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Tieu HVN; Laboratory of Infectious Disease Prevention, New York Blood Center, New York, New York, United States of America., Frank I; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America., Sobieszczyk ME; Division of Infectious Diseases, Columbia University Medical Center, New York, New York, United States of America., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Sanchez B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Latham TE; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Clarke DK; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Egan MA; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Eldridge JH; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Hannaman D; Ichor Medical Systems, Incorporated, San Diego, California, United States of America., Xu R; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., Ota-Setlik A; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.; Department of Global Health, University of Washington, Seattle, Washington, United States of America.; Department of Medicine, University of Washington, Seattle, Washington, United States of America., Hay CM; Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York, United States of America.

مؤلفون مشاركون: NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team

المصدر: PloS one [PLoS One] 2018 Sep 20; Vol. 13 (9), pp. e0202753. Date of Electronic Publication: 2018 Sep 20 (Print Publication: 2018).

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: AIDS Vaccines/*administration & dosage , Genetic Vectors/*administration & dosage , Interleukin-12/*genetics , Vaccines, Attenuated/*administration & dosage , Vaccines, DNA/*administration & dosage , Vesicular stomatitis Indiana virus/*genetics, AIDS Vaccines/adverse effects ; Adult ; Combined Modality Therapy ; Double-Blind Method ; Electroporation ; Female ; Genetic Vectors/adverse effects ; HIV-1 ; Healthy Volunteers ; Humans ; Immunization, Secondary ; Injections, Intramuscular ; Male ; Middle Aged ; Plasmids/genetics ; Vaccines, Attenuated/adverse effects ; Vaccines, DNA/adverse effects ; Young Adult ; gag Gene Products, Human Immunodeficiency Virus